Compare Biogen Inc (BIIB) vs Realty Income Corp (O) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Biogen Inc vs Realty Income Corp — how do they compare? Biogen Inc trades at $195.24 (market cap $28.34B), while Realty Income Corp trades at $63.87 (market cap $59.47B). The key difference: Realty Income Corp is far larger — about 2.1× Biogen Inc's market cap, and Realty Income Corp pays a 5.1% dividend while Biogen Inc pays none. Which is the better fit depends on your goals.
| BIIB | O | |
|---|---|---|
Market Cap | $28.34B | $59.47B |
Sector | Health | Real Estate |
52-Week High | $216.63 | $67.56 |
52-Week Low | $122.68 | $55.93 |
Enterprise Value | $30.62B | $89.27B |
Dividend Yield | — | 5.1% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Biogen (BIIB) trades at $209.03, up 4.96% today, with a bullish technical signal and strong analyst support. Recent quarterly earnings have consistently beaten expectations, and the company maintains solid profitability with a 75.49% gross margin. Key developments include FDA approval for a subcutaneous starter dose of Leqembi and promising Phase 2 data for its Alzheimer's drug diranersen, driving positive sentiment.
The outlook is positive, with a consensus price target of $230.18 suggesting upside. Investment opportunities lie in Alzheimer's pipeline advancements, but risks include clinical trial outcomes and competitive pressures. Revenue stability and cost management support fundamentals, though regulatory hurdles remain a watchpoint.
Realty Income (O) trades at $64.17, up 1.36% with a bullish technical outlook. The stock shows strong fundamentals with $5.75B revenue and 19.05% net income margin, though recent quarters have missed EPS estimates. Recent credit facility expansion to $5.5B supports growth initiatives, particularly in European markets. Dividend payments remain consistent at $0.27 quarterly, providing stable income for investors.
Outlook remains positive with analyst consensus target of $67.86 representing 5.8% upside. Risks include elevated P/E ratio of 51.89 and three consecutive quarterly earnings misses. The company's expansion strategy and strong cash flow generation support long-term growth potential, though valuation concerns warrant monitoring of future earnings performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Biogen Inc
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →About Realty Income Corp
Realty Income owns roughly 11,400 properties, most of which are freestanding, single-tenant, triple-net-leased retail properties. Its properties are located in 49 states and Puerto Rico and are leased to 250 tenants from 47 industries. Recent acquisitions have added industrial, office, manufacturing, and distribution properties, which make up roughly 17% of revenue.
Read more on O →
